Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
908 Devices Inc. (MASS) delivers innovative mass spectrometry solutions enabling real-time chemical analysis across safety, life sciences, and industrial sectors. This news hub provides investors and professionals with essential updates on corporate developments and technological advancements.
Access timely press releases, earnings reports, and strategic announcements in one centralized location. Our curated collection includes regulatory filings, product launch details, and partnership updates critical for understanding the company's market position.
Key updates cover:
- Financial performance and investor communications
- Breakthroughs in handheld/desktop analysis devices
- Industry-specific applications in biotech and forensics
- Global expansion initiatives and regulatory milestones
Bookmark this page for streamlined access to MASS's evolving story. Combine our news archive with SEC filings and market analysis tools for comprehensive due diligence.
908 Devices (Nasdaq: MASS) has secured a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module, scheduled for priority shipment in Q1 2025.
The MX908 devices, featuring proprietary High Pressure Mass Spectrometry (HPMS) technology, will be integrated into environmental testing kits for post-war applications. The system is designed to detect and identify trace levels of hazardous materials, including explosives, chemical agents, and priority drugs.
The Aero module enhancement enables rapid detection of aerosolized threats, including chemical warfare agents, pharmaceutical-based agents, and opioid analogs, providing first responders with critical actionable information for public safety.
908 Devices (NASDAQ: MASS) announced a strategic transformation and Q4/FY2024 financial results. The company divested its desktop portfolio to Repligen for $70 million, strengthening its focus on handheld chemical analysis devices.
Key financial highlights include:
- Q4 2024 revenue: $18.8M (+31% YoY)
- Full year 2024 revenue: $59.6M (+19% YoY)
- Handheld revenue: $46.1M (+22% YoY)
- Recurring revenue: $23.3M (39% of total revenue)
The company expects 11-15% revenue growth in 2025, with anticipated acceleration above 20% in 2026. The transformation reduces headcount by 33%, eliminates $20M in annual operating losses, and aims to achieve Adjusted EBITDA positivity by Q4 2025 and cash flow positivity in 2026. Gross margins are projected to reach mid-to-high 50% range in 2025.
Repligen (RGEN) has acquired the desktop bioprocessing analytics portfolio from 908 Devices (MASS) for $70 million in cash. The acquisition includes four PAT (Process Analytical Technology) devices: MAVERICK, MAVEN, REBEL, and ZipChip.
The acquired technologies enable real-time monitoring, control of bioprocess parameters, cell culture media analysis, and high-resolution sample separations for product quality characterization. This strategic move strengthens Repligen's PAT portfolio and expands its capabilities across the entire bioprocess workflow.
Following the transaction, 908 Devices will focus on growing its handheld device portfolio for health and safety applications. The deal includes the transfer of 908's bioprocessing team to Repligen.
908 Devices (Nasdaq: MASS), a pioneer in handheld and desktop chemical analysis devices, has announced its participation in two major investor conferences. The company will be featured in:
- A fireside chat at the TD Cowen 45th Annual Healthcare Conference in Boston on March 5 at 9:50 a.m. Eastern Time
- A fireside chat at the Leerink Global Healthcare Conference in Miami on March 11 at 1:00 p.m. Eastern Time
Investors and interested parties can access live and archived webcasts of both sessions through the company's investor relations website at www.908devices.com.
908 Devices (Nasdaq: MASS), a pioneer in handheld and desktop chemical analysis devices, has scheduled its fourth quarter and full year 2024 financial results announcement for March 4, 2025, before market open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results. Investors can access the live audio webcast through the company's website investor section, with a replay available within 24 hours after the event.
908 Devices (Nasdaq: MASS) announced preliminary unaudited financial results for Q4 and full year 2024. Q4 revenue is expected to reach $17.2 million, up 20% from $14.4 million in Q4 2023. Full-year 2024 revenue is anticipated at $58.0 million, showing 15% growth compared to $50.2 million in 2023, meeting the high end of revenue guidance.
Both handheld and desktop revenues showed double-digit growth year-over-year in Q4, with desktop revenues also growing sequentially. The RedWave Technology acquisition, completed in April 2024, is expected to meet its post-acquisition revenue target of $11 million for approximately 8 months of ownership, delivering double-digit pro-forma growth. The company consumed about $2 million in cash during Q4, ending with $69.5 million in cash, cash equivalents, and marketable securities.
908 Devices (Nasdaq: MASS) and Getinge have announced a partnership to integrate their technologies for enhanced bioreactor monitoring. The collaboration combines Getinge's bioreactors with 908 Devices' MAVEN system for automated control of glucose and lactate levels in cell cultures.
The integrated solution enables continuous, real-time analysis without manual sampling, allowing biopharma scientists to maintain optimal nutrient concentrations. MAVEN can monitor up to two bioreactors simultaneously, with data being managed through Getinge's advanced controllers. The system will be compatible with Getinge's Livit Flex controller and connected through Livit Links sensor ports.
908 Devices (Nasdaq: MASS) reported a 17% increase in Q3 2024 revenue to $16.8 million, driven by newly acquired handheld products. However, challenges included the delayed FY24 federal budget, international contract delays, and softness in the bioprocessing and life science instrumentation market. Handheld revenue rose 19% to $14.0 million, while desktop revenue increased 8% to $2.8 million. Recurring revenue surged 70% to $6.1 million, making up 36% of total revenue. The company ended the quarter with $71.7 million in cash and no debt. Despite a net loss of $29.3 million and an adjusted EBITDA loss of $6.9 million, 908 Devices expects full-year 2024 revenue to range between $56 million and $58 million, a growth of 11%-15% over 2023. Structural changes include transitioning manufacturing to North Carolina and Connecticut, reducing operating expenses, and integrating the sales organization for efficiency.
908 Devices (Nasdaq: MASS), a company specializing in handheld and desktop chemical analysis devices, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the Stifel Healthcare Conference in New York on November 19 at 8:35 a.m. Eastern Time, and at the 26th Annual Stephens Investment Conference in Nashville on November 20 at 4 p.m. Eastern Time. Live and archived webcasts of both sessions will be available on the company's website investor section.
908 Devices Inc. (Nasdaq: MASS), a pioneer in handheld and desktop chemical analysis devices, has announced its plan to release third quarter 2024 financial results on Tuesday, November 12, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on the same day to discuss the results.
Interested parties can access the live audio webcast on the "Investors" section of the company's website at www.908devices.com. For those unable to attend the live event, an archived version of the webcast will be made available for replay within 24 hours after the event concludes.